Arena Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise nearly 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company—as the stock is now down 10.1% in the past one-month time frame.

The move came after the company reported positive phase 2 results from the OASIS trial for etrasimod in patients with ulcerative colitis.

The company has seen one negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Arena Pharmaceuticals, Inc. Price

Arena Pharmaceuticals, Inc. Price | Arena Pharmaceuticals, Inc. Quote

Arena Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

A better-ranked stock in the Medical  sector is Regeneron Pharmaceuticals, Inc. (REGN Quick QuoteREGN - Free Report) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is ARNA going up? Or down? Predict to see what others think: Up or Down

Zacks Editor-in-Chief Goes "All In" on This Stock

Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.

Download it free >>